[
  {
    "ts": null,
    "headline": "Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025",
    "summary": "WILMINGTON, Del., July 24, 2025--Data for Incyte's TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and Selective Inhibitor of G12D-mutated KRAS (INCB161734) Accepted at ESMO 2025",
    "url": "https://finnhub.io/api/news?id=e68c848a0ceb434ecd646949a1867a71b13f763ece1b494c2bddb5c6f026097b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753390920,
      "headline": "Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025",
      "id": 136085791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., July 24, 2025--Data for Incyte's TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and Selective Inhibitor of G12D-mutated KRAS (INCB161734) Accepted at ESMO 2025",
      "url": "https://finnhub.io/api/news?id=e68c848a0ceb434ecd646949a1867a71b13f763ece1b494c2bddb5c6f026097b"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?",
    "summary": "INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.",
    "url": "https://finnhub.io/api/news?id=49ef6093c3a31eb12ebb731190d9da0ffe7f12aa4b7cf70b72c41feb757becb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753371720,
      "headline": "Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?",
      "id": 136085792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.",
      "url": "https://finnhub.io/api/news?id=49ef6093c3a31eb12ebb731190d9da0ffe7f12aa4b7cf70b72c41feb757becb0"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release",
    "summary": "Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=64a8ec117c0b699a0c6a0483810f89e84a61b8d52b568b92f28b813579dce5c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365626,
      "headline": "Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release",
      "id": 136066935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=64a8ec117c0b699a0c6a0483810f89e84a61b8d52b568b92f28b813579dce5c1"
    }
  }
]